This afternoon I received a Google Alert about a new study on curcumin and myeloma. I got so excited that I could barely finish reading the abstract! (see: http://tinyurl.com/mc8vth)
I have already asked my dear Sherlock if she can get her hands on the full study. In the meantime, the abstract informs us that 26 MGUS patients were given a daily dose of four grams of curcumin. Hmmm, come to think of it, these must be more results from the Australian MGUS-curcumin trial that I posted about on March 13 2009. Yes, I am sure of it…same names, same hospital. Well, well.
Let’s go directly to the results, which show that oral curcumin is able to decrease paraprotein load in a select group (i.e., those having a paraprotein level of >20 g/L) of patients with MGUS. Fifty percent (5 of 10) of these patients had a 12% to 30% reduction in their paraprotein levels, while on curcumin therapy. In addition, 27% of patients on curcumin had a >25% decrease in urinary N-telopeptide of type I collagen.
I’d never heard of this urinary peppy thingy, so I had to look it up. I found a study that explains its significance for myeloma patients: http://tinyurl.com/lqls9e Basically, it is a sensitive and specific marker of bone resorption in multiple myeloma. High levels of urinary N-telopeptide of type I collagen, or NTx, are found at advanced stages of disease. Okay, so the lower, the better.
But hey!, have a look at the Conclusions: Due to the possible progression of MGUS to multiple myeloma, the potential role of curcumin as a therapeutic intervention for MGUS patients warrants further investigation. Well, I’ll be…! Just knock me down with a Tetris tile! Oh, I can’t wait to read the whole shebang…!!!